Group 1 - Beyond (BYON) shares have increased by 18.9% over the past four weeks, closing at $8.95, with a mean price target of $14.08 indicating a potential upside of 57.3% [1] - The average price targets range from a low of $5.00 to a high of $36.00, with a standard deviation of $11.06, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for BYON's current year earnings has risen by 17.5% over the past month, with two estimates increasing and no negative revisions [12] - BYON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Hillman Solutions Corp. (HLMN) closed at $8, with a 5.3% gain over the past four weeks, and has a mean price target of $10.94, indicating a 36.8% upside potential [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $2.54, where the lowest estimate is $8.00 and the highest is $15.00, suggesting an 87.5% potential increase [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 0.6% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - HLMN has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] - While price targets should not be the sole basis for investment decisions, the direction they imply appears to be a good guide for potential price movements [14]

Core Viewpoint - GDS Holdings (GDS) has shown a significant price increase of 14.4% over the past four weeks, with a mean price target of $44.17 indicating a potential upside of 25.2% from the current price of $35.27 [1] Price Targets and Analyst Consensus - The average price target for GDS includes 12 estimates ranging from a low of $28.30 to a high of $64.54, with a standard deviation of $9.75, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 19.8%, while the highest points to an 83% upside potential [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about GDS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 5.1% over the past month, with one estimate increasing and no negative revisions [12] - GDS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to historical inaccuracies in predicting actual stock movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8] - Despite the skepticism surrounding price targets, the direction they imply can still serve as a useful guide for potential stock movements [14]

Core Viewpoint - Dyne Therapeutics, Inc. (DYN) shows significant upside potential with a mean price target of $38.21, indicating a 285.6% increase from the current trading price of $9.91 [1] Price Targets and Estimates - The mean estimate consists of 17 short-term price targets with a standard deviation of $14.79, suggesting variability in analyst predictions. The lowest estimate is $9.00 (9.2% decline), while the highest is $66.00 (566% increase) [2] - Analysts' price targets can be misleading, as empirical research indicates they rarely accurately predict stock price movements [7][10] Earnings Estimates - Analysts have shown increasing optimism regarding DYN's earnings, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.1%, with four estimates moving higher and no negative revisions [12] Analyst Rankings - DYN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of DYN's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Zevra Therapeutics (ZVRA) has seen a 16.8% increase in share price over the past four weeks, closing at $10.99, with analysts suggesting a potential upside of 117.1% based on a mean price target of $23.86 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $3.39, indicating a range of potential outcomes; the lowest estimate is $19.00 (72.9% increase), while the highest is $29.00 (163.9% increase) [2][9]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction, although it does not guarantee that the stock will reach the average target [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ZVRA's earnings prospects, as indicated by a significant increase in earnings estimate revisions, with a 337.1% rise in the Zacks Consensus Estimate for the current year [11][12]. - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for near-term upside [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the positive direction indicated by earnings estimate revisions appears to be a valid guide for potential stock price movements [14].

Group 1 - Shares of uniQure (QURE) have increased by 1.3% over the past four weeks, closing at $14.46, with a mean price target of $35.09 indicating a potential upside of 142.7% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $17.1, where the lowest estimate is $13.00 (10.1% decline) and the highest is $70.00 (384.1% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions suggesting potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% due to one upward revision in the last 30 days, with no negative revisions [12] - QURE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Netflix (NFLX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Netflix currently has an average brokerage recommendation (ABR ...

Check price target & stock forecast for Robinhood Markets here>>> While the ABR calls for buying Robinhood Markets, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-fi ...

Group 1 - Analysts forecast PSEG (PEG) will report quarterly earnings of $0.71 per share, reflecting a year-over-year increase of 12.7% [1] - Anticipated revenues for the quarter are $2.34 billion, showing a decrease of 3.2% compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Group 2 - Revenue for PSE&G is expected to reach $1.97 billion, indicating a year-over-year change of +5.6% [3] - Revenue from Power & Other is projected at $453.29 million, representing a decline of -33.7% from the prior-year quarter [4] - The consensus estimate for total gas sold and transported is 543 million dekatherm, slightly down from 550 million dekatherm a year ago [4] Group 3 - Analysts estimate 'Gas Sold and Transported - Total Non-Firm Sales' at 176 million dekatherm, down from 191 million dekatherm in the previous year [5] - 'Gas Sold and Transported - Total Firm Sales' is expected to be 366 million dekatherm, compared to 359 million dekatherm reported last year [6] - Operating Income for Power & Other is forecasted to be $72.68 million, down from $115.00 million in the prior year [6] Group 4 - Operating Income for PSE&G is projected to reach $527.13 million, an increase from $467.00 million reported last year [7] - PSEG shares have increased by +9.4% in the past month, outperforming the Zacks S&P 500 composite's +2.7% [7] - PSEG holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago. These figures are adjusted for non- recurring items. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earning ...